Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.




### 上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)


(Stock Code: 02196)




As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

\* for identification purposes only

#### **1. IMPORTANT NOTICE**



2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP



		, L: L	C, ., : MB
Items	Amounts during the Reporting Period (Jul – Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan – Sep 2014)	Description
and the general the second and se	97,665,175.84	191,310,773.56	
$ \begin{array}{c} G \\ ( \begin{array}{c} \cdot \\ \cdot $	7,521,005.13	20,952,587.13	
	90,352,768.11	617,479,614.88	
Not state in the last of the	-710,975.01	-4,388,950.98	
	98,487.91	-16,101,512.09	
E, N. C.	-48,001,772.19	-202,411,118.11	
	14,245,629.96	-24,635,526.51	
	161,170,319.75	582,205,867.88	

. L : 10

, <u>, , , , , , , , , , , , , , , , , , </u>						73,142
The	shareholding s	status of the <b>T</b>	op 10 sharehol	ders		
	Shareholding at the end of	Percentage	Number of restricted	-	Shares pledged or locked up	
Name of shareholders (full name)	the period	(%)	shares held	Status	Number	
HANGHAI F $\bullet$ N HIGH ECHN $\bullet$ L $\bullet$ G (G $\bullet$ ) C $\bullet$ M AN LIMI ED ("F, r G, r")	920,641,314	39.83	0	Ŋ.	0	D, ,
HK CC NOMINEE LIMI ED (N. 1)	402,619,300	17.42	0	* * , *	0	- L <sup>1</sup>
CHINA EC I IE FINANCE CO A ION LIMI ED	69,112,399	2.99	0	Ŋ.	0	* *, *
NA IONAL OCIAL EC I F ND	37,199,998	1.61	0	Ŋ.	0	* *, *
HONG KONG EC I IE CLEA ING COM AN LIMI ED (N. 2)	33,556,005	1.45	0	Ŋ.	0	+ +, +
CEN ALH IJIN NE MEN LD.	24,067,700	1.04	0	Ŋ.	0	
$\checkmark$ INH A LIFE INANCE CO., L D DI IDEND - G O DI IDEND- 018L - FH001 HANGHAI*	22,652,864	0.98	0	Ŋ.	0	+ + j +
ING CA I AL (BEIJING) CO., L D — ING CA I AL G O H F ND NO. I*	17,695,247	0.77	0	Ŋ.	0	* *, *
F• IC JING ELEC ED 1*	16,764,537	0.73	0	Ŋ.	0	* • • •
ING AN CO, L D — ELI E IN E MEN • ING CA I AL	16,567,783	0.72	0	Ŋ.	0	

The shareholding status	s of the Top 10 unrestric	ted shareholders	
	Number of	Type and num	ber of shares
Name of the shareholders	unrestricted tradable shares held	Туре	Number
F G	920,641,314	MB L	920,641,314
HK CC NOMINEE LIMI ED (Note 1)	402,619,300		402,619,300
CHINA EC I IE FINANCE CO O A ION LIMI ED	69,112,399	MB	69,112,399
NA IONAL OCIAL EC I F ND 104	37,199,998	MB, MB	37,199,998
H $ oldsymbol{eq}$ NG K $ oldsymbol{eq}$ NG C $ oldsymbol{eq}$ AN LIMI ED ( <i>Note 2</i> )	33,556,005	MB, MB	33,556,005
CEN ALH IJIN IN E MEN LD.	24,067,700	MB	24,067,700
<pre>#INH A LIFE IN ANCE C●., L D. — DI IDEND</pre>	22,652,864	MB	22,652,864
ING CA I AL (BEIJING) CQ., L D — ING CA I AL G Q H F ND NQ. I*	17,695,247	MB, MB	17,695,247
FQ IC ING ELEC ED 1*	16,764,537	MB L	16,764,537
ING AN CO., L D — ELI E IN E MEN • ING CA I AL	16,567,783	MB	16,567,783
	G 💽 H F ND NO.	ELIE IN E MEN ING CAIAL (BE	LEC ED 1* ING ING CAIAL
	N ATL AL		

Note 1: HK CC NOMINEE LIMI ED,  $\dots$  H,  $K_{r_1}$  Y,  $C_{r_1}$  C, N L, N L,

#### 3. SIGNIFICANT EVENTS



		Balance Sl	neet	·
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons 👞
¢h s twγL	485,549,599.95	198,755,576.52	144.29%	
A the second sec		990,340,787.62	-100.00%	
	3,494,730.03	11,246,964.92	-68.93%	
	3,529,897,004.62	2,499,156,438.67	41.24%	
	167,214,321.23	89,379,481.02	87.08%	Mili ki, i &Di i i
k, − r×	4,508,065,870.77	2,841,223,392.47	58.67%	
ya tyayar	474,418,367.92	342,926,461.15	38.34%	
	14,831,357.70	1,279,819.25	1,058.86%	
$ \begin{bmatrix} L_{\lambda} \mathbf{q} & \mathbf{i} & \mathbf{i} & \mathbf{i} \\ \mathbf{q} & \mathbf{j} & \mathbf{i} & \mathbf{i} \\ \mathbf{k} & \mathbf{j} & \mathbf{j} & \mathbf{j} \end{bmatrix} = \begin{bmatrix} \mathbf{i} & \mathbf{j} & \mathbf{j} \\ \mathbf{k} & \mathbf{j} & \mathbf{j} \end{bmatrix} $		589,118,424.34	-100.00%	(N, )
	2,822,255,623.13	1,109,525,523.85	154.37%	Mլս , ի նչ, ս ս- ,, լ մես Հ/ԳՀ , ս, պես ,
	63,116,411.43	1,070,561,681.96	-94.10%	
L, , , - , , , , , , , , , , , , , , , ,	1,618,247,844.35	771,191,646.56	109.84%	
B	1,894,480,886.28	3,085,482,735.30	-38.60%	

		Income State	ement	
	Current amount	Amount of the last period		
Items	Jan – Sep 2015	Jan – Sep 2014	Ratio of change	🔌 Reasons
Fi A	339,686,256.62	251,024,209.33	35.32%	
A tot r	33,340,027.70	11,784,007.60	182.93%	
Get a star the set	3,506,487.53	-9,516,778.44	136.85%	
Net NI NI	63,499,502.52	38,512,060.43	64.88%	
Net NI C	10,862,409.73	15,531,263.99	-30.06%	
Φhi so y his ik tso	-279,141,519.38	146,057,212.28	-291.12%	

Statement of Cash Flow					
	Current amount	Amount of the last period			
Items	Jan – Sep 2015	Jan – Sep 2014	Ratio of change	Reasons	
	1,161,951,526.99	843,637,595.71			
	764,402,303.12	1,793,987,740.16			

 Note:
 I 2014, C
 2014, C

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure
 Image: Second structure

 Image: Second structure
 Image: Second struct

2015, 41 ( <sub>1</sub>) <u>n</u> n' ۳. ۲. ۲۰۰۲ C 2015 ( II ( ) C ( MB10.82 **1 1 1 7 1**  


 MB10.82
 47
 4
 4
 M, b
 2015, b
 C


 C.,L.\*
 A
 I,
 , b
 "(b)
 B, H,
 2015, b
 C


 於上海
 星醫藥(集團)股份有限公司股權激勵計劃意見的函》(上市部函 2015, 215號))

  $\begin{array}{c} \mathbf{L} \\ \mathbf{L} \\ \mathbf{C} \\ \mathbf{$ Į,, II. • 25  $A_{111}$  2015, •  $A_{11}$ ι,  $\begin{array}{c} \mathbf{b} \quad \mathbf{B} \\ \mathbf{C} \\ \mathbf{$ ι<sub>τ</sub> **ب**\_\_) ) ا Ç k, Α ), Ĭ, ⊾<sup>k</sup>Ĭ II 🖡 Ç IIU 2,719,000 IК · • • • • • 2,704,000 k I, , I, I, Ç в, 2,704,000 I **b** , <sub>1</sub>, ۰<sub>1</sub>, ۲ ۱, Î Ç A Η L C (2) I 2013 Č 

 C
 3 A
 2015, C
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 <t ▶ "N, A, 3 Å 1 2015, ۰ I ، ι<u>κ</u>\_' Ér 🦷 **( )** L B Ç ( t Е 🚬 -І 🦆 







Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* L 29 2015

#### **APPENDICES** 4.

#### 4.1 Financial statements

#### **Consolidated balance sheet**

30 September 2015

## : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

	: <sub>LX</sub> C <sub>L</sub> , : MB			
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year		
Current Assets:				
	3,516,813,404.78	3,695,698,185.8		
L L L L L				
	38,724,495.54	33,770,584.1		
	408,527,911.80	472,523,132.7		
	1,789,464,377.02	1,504,149,790.7		
	136,605,468.61	137,690,114.0		
	677,257.70	1,023,889.4		
	16,983,973.47	14,264,402.9		
	485,549,599.95	198,755,576.5		
	1,627,321,198.79	1,604,562,390.		
		990,340,787.		
• k	3,494,730.03	11,246,964.9		
	8,024,162,417.69	8,664,025,819.1		
Non-current assets.				
Alles en presentations				
$A_{1} \underbrace{\mathbf{u}_{1}}_{\mathbf{x}_{1}} = \underbrace{\mathbf{u}_{1}}_{\mathbf{x}_{2}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1}} \underbrace{\mathbf{u}_{1$	3,529,897,004.62	2,499,156,438.0		
$L_{r_1}^{k} = \mathbf{N}, \ \mathbf{u}_{\mathbf{k}-1}^{k}$				
	13,489,435,775.47	11,905,750,117.		
Fu <sup>°</sup>	4,720,292,409.25	4,623,958,317.0		
	964,172,888.14	1,051,988,109.		
	3,233,982.94	5,450,698.		
	2,857,317,020.41	2,822,483,093.		
	167,214,321.23	89,379,481.		
G, t,	3,292,538,591.11	3,255,041,739.		
	11,804,369.09	13,583,440.		
D	92,366,614.48	101,221,671.		
	262,125,551.28	304,238,328.4		
	29,390,398,528.02	26,672,251,436.		
	37,414,560,945.71	35,336,277,255.		

#### **Consolidated balance sheet** (*Continued*)

30 September 2015

lance end riod	Opening balance as at the beginning of the Year
1100	of the rear
065,870.77	2,841,223,392.47
,	_,,,.,,
928,606.53	70,987,451.05
465,599.33	833,974,948.21
002,022.22	266,518,255.34
895,628.48	298,472,746.11
418,367.92	342,926,461.15
803,873.32	177,075,081.31
831,357.70	1,279,819.25
103,280.44	1,935,656,885.83
	589,118,424.34
255,623.13	1,109,525,523.85
116,411.43	1,070,561,681.96
886,641.27	9,537,320,670.87
,.	- ,,
247,844.35	771,191,646.56
480,886.28	3,085,482,735.30
883,419.71	710,056,624.65
123,561.73	139,593,190.51
427,964.42	1,929,331,107.42
391,869.13	60,299,392.99
555,545.62	6,695,954,697.43
442,186.89	16,233,275,368.30
200 264 00	0 211 611 264 00
380,364.00 708,237.59	2,311,611,364.00 6,123,454,191.14
100,231.39	0,123,434,191.14
468,407.81	1,120,365,125.73
373,054.64	1,662,373,054.64
	-,,,,
890,376.05	5,457,045,050.64
820,440.09	16,674,848,786.15
298,318.73	2,428,153,101.51
118,758.82	19,103,001,887.66
560,945.71	35,336,277,255.96
11	8,758.82

Legal Representative: Chen Qiyu

Chief Financial Officer: Guan Xiaohui Director of the Accounting Department: Yan Jia

#### **Balance Sheet of the Parent Company (***Continued***)**

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
k,	1,834,226,000.00	
Figure 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,		
Bu		
	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
I.A. A.A.	147,159,729.00	160,716,398.26
	1,364,923.50	1,062,450.00
¢k	453,068,674.16	587,606,051.26
	2,641,935,028.99	1,037,216,423.85
et si		998,894,520.55
	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
	186,740,000.00	85,000,000.00
B. A.	1,894,480,886.28	3,085,482,735.30
	1,525,000.00	1,750,000.00
	1,209,260,573.79	1,192,857,263.79
<b>• • • • • • •</b>		
	3,292,006,460.07	4,365,089,999.09
	8,472,326,130.16	7,244,996,708.94
Equity:		
ιι, , , , , , (	2,311,380,364.00	2,311,611,364.00
C, L,	8,227,835,906.44	8,270,816,715.22
, sty V		
ek sy jiku usy	55,747,958.04	224,689,817.57
	949,985,460.52	949,985,460.52
G. L. C. LU.		
	4,193,926,575.18	2,839,595,396.66
	15,738,876,264.18	14,596,698,753.97
	24,211,202,394.34	21,841,695,462.91

Legal Representative: Chen Qiyu

Guan Xiaohui

Chief Financial Officer: Director of the Accounting Department: Yan Jia

#### **Consolidated Income Statement**

January – September 2015



# : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

		ì		
	, t :	ir C <sub>i</sub> , :	MB	1.1 - <sub>M</sub> 1.
Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I Ly		, , ,	, , ,	, , ,
E				
F y y the ty				
II.	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
	-,,, ,	-,,	.,,	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F yr yr thr yr				
C				
N N N N N N N N N N N N N N N N N N N				
B <sub>1</sub> , b <sub>1</sub> , b <sub>1</sub>	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
FL, s. s.	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
A	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60
· · · · · · · · · · · · · · · · · · ·				
	1			

#### **Consolidated Income Statement (***Continued***)**

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
L Oh sy philipping and	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
(u) <b>Q</b>				
	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
آ، او پر او پر او پر او پر او پر او پر او او پر او پر او پر او پر او پر او	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3. G				
5. E. I	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
I I Jan Jan Jack Carl	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
	0.25	0.24	0.82	0.00
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	0.25	0.24	0.82 0.82	0.69

Legal Representative: Chen Qiyu


Guan Xiaohui

Chief Financial Officer: Director of the Accounting Department: Yan Jia

I	1	I	I	l

#### **Consolidated Statement of Cash Flow**

January – September 2015



•

μι: <sub>ιχ</sub>	C <sub>L</sub> , MB	, <sub>XI</sub> I: , <sub>XI</sub> I
Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Cash flow generated from operating activities:		
	11,787,872,270.19	10,459,786,860.15
N the second sec		
N $\mathbf{t}_{1}$ $(\mathbf{t}_{1}, \mathbf{t}_{2}, $		
N, L, L, L, L, L, L		
N to the test the start the start		
N to the provident of the		
	30,317,198.52	72,648,588.55
	97,662,080.84	94,521,561.68
	11,915,851,549.55	10,626,957,010.38
	6,127,603,506.07	6,154,725,576.22
$N(t, \frac{1}{2}), \frac{1}{2}, \frac{1}$		
Nus prukszy pr		
$= C_{\mu} \frac{1}{\rho_{\mu}} \frac{1}{\rho_{$		
C to the the second sec	1,406,092,878.78	1,216,716,910.44
	1,055,403,620.12	851,073,785.17
M Sherry Line Content	2,164,800,017.59	1,560,803,142.84
	10,753,900,022.56	9,783,319,414.67
N , , , , , , , , , , , , , , , , , , ,	1,161,951,526.99	843,637,595.71
II. Cash flow generated from investing activities:		
<u>Christian Christian Christian</u>	856,889,234.08	1,024,268,371.05
Charles and a second se	100,352,896.71	88,024,272.04
N she she is he was	9,861,620.38	90,869,547.68
N , او با بار او با از او با بار او با	315,852,788.57	48,736,636.59
	107,075,600.48	439,566,546.01
	1,390,032,140.22	1,691,465,373.37
	738,403,167.55	855,603,820.63
	2,327,525,471.23	1,732,041,861.35
N		
	45,071,121.94	628,770,325.12
$\Phi = \frac{1}{\sqrt{2}} \left[ \frac{1}{\sqrt{2}}$	182,668,212.99	246,994,986.24
	3,293,667,973.71	3,463,410,993.34
	-1,903,635,833.49	-1,771,945,619.97


### Consolidated Statement of Cash Flow (Continued)

January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
	87,721,195.00	1,445,949,451.00
Istration and the second secon	87,721,195.00	38,269,850.07
	5,110,056,682.54	3,475,109,758.30
	398,929,000.00	1,000,000,000.00
( <b>0</b> , <b>1</b> , 1	40,140,014.05	21,733,509.09
	5,636,846,891.59	5,942,792,718.39
	3,519,139,442.58	1,623,242,732.68
	1,114,614,719.91	1,012,768,967.52
	268,686,768.21	133,554,721.22
	238,690,425.98	1,512,793,278.03
	4,872,444,588.47	4,148,804,978.23
	764,402,303.12	1,793,987,740.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V. Net increase of cash and cash equivalents	28,667,545.61	88

#### Statement of Cash Flow of the Parent Company

January – September 2015



	(	
μ.: <sub>ι</sub>	κ C <sub>L</sub> , : MB	
Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Cash flow generated from operating activities:		
	450,000.00	450,000.00
	17,027,016.02	24,262,470.46
	17,477,016.02	24,712,470.46
C. A.	76,034,052.14	55,675,865.31
C. L.	34,051,409.56	38,638,399.47
	46,784,926.39	28,772,270.22
	156,870,388.09	123,086,535.00
	-139,393,372.07	-98,374,064.54
II. Cash flow generated from investing activities:		
	246,952,337.32	
	341,508,734.72	135,001,207.03
	۲ <sup>-1</sup>	150,000.00
		10,351,169.50
		408,839,600.00
	588,461,072.04	554,341,976.53
Charles and the state of the st	1,023,410.77	3,334,618.53
	1,286,782,424.70	1,780,579,380.37
		27,023,100.00
		20,000,000.00
	1,287,805,835.47	1,830,937,098.90
	-699,344,763.43	-1,276,595,122.37
III. Cash flow generated from financing activities:		
		1,407,679,600.93
	2,281,014,000.00	850,000,000.00
	398,929,000.00	1,000,000,000.00
	4,785,211,767.92	4,754,495,093.76
	7,465,154,767.92	8,012,174,694.69
	1,345,000,000.00	601,000,000.00
	880,988,031.73	829,585,897.32
	4,263,390,819.81	4,365,392,837.67
	6,489,378,851.54	5,795,978,734.99
	975,775,916.38	2,216,195,959.70
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-4,232,440.84	9,803,068.68
V. Net increase of cash and cash equivalents	132,805,340.04	851,029,841.47
	506,943,460.86	519,292,385.71
VI. Closing balance of cash and cash equivalents	639,748,800.90	1,370,322,227.18

Legal Representative: Chen Qiyu Chief Financial Officer: Guan Xiaohui Director of the Accounting Department: Yan Jia

#### 4.2 Audited Report

•